In light of various publications highlighting the importance of IL-6/IL-6R signaling in ovarian tumor biology and the results described here, we are supportive of clinical trials to study whether antagonizing IL-6R is a viable treatment strategy for ovarian cancer. This evidence concerns the gene IL6 and ovarian neoplasm.